UCLA Study: Switching From Cigarettes to Smokeless Tobacco Lowers Heart Disease Risk

Innovation
Jul.28.2022
A study published today in the journal Nicotine and Tobacco Research, highlights the relative safety of smokeless tobacco products and how switching to the products from combustible cigarettes was associates with lower cardiovascular disease risk in smokers.

Participants who were current smokeless tobacco users and former smokers, still had lower levels of both inflammatory and oxidative stress biomarkers and tobacco exposure biomarkers than current exclusive cigarettes smokers.

 

UCLA Study: Switching From Cigarettes to Smokeless Tobacco Lowers Heart Disease Risk

The study, “Associations of Smokeless Tobacco Use With Cardiovascular Disease Risk: Insights From the Population Assessment of Tobacco and Health Study” was conducted by a team of researchers from UCLA, UC San Francisco, Boston University and the University of Texas at Arlington.

 

The researchers analyzed data from a nationally representative group of 4,347 adults who provided urine and blood samples in 2013–14 as part of the Population Assessment of Tobacco and Health (PATH) Study. Among this group, 3,034 participants used cigarettes exclusively, 338 used only smokeless tobacco, and 975 had never used any tobacco product.

 

The research team analysed the participants’ samples for biomarkers of tobacco exposure, inflammation and oxidative stress, which are predictors of cardiovascular disease risk, in each of the three subgroups.

 

The compiled data indicated that despite similar nicotine levels, smokeless tobacco users displayed significantly lower biomarkers of disease. “Our findings show that despite having higher levels of nicotine, exclusive smokeless tobacco users had significantly lower concentrations of inflammation and oxidative stress biomarkers than cigarette smokers. Levels of these biomarkers among smokeless tobacco users were similar to those of ‘never’ smokers,” said lead study author Mary Rezk-Hanna, who is an assistant professor at UCLA School of Nursing.

 

Former smokers using smokeless tobacco had less oxidative stress than smokers

 

The findings also revealed that the participants who were current smokeless tobacco users and former smokers, still had lower levels of both inflammatory and oxidative stressbiomarkers and tobacco exposure biomarkers than current exclusive cigarettes smokers, even though they had higher nicotine levels. Roughly 84% of both groups were daily tobacco users.

 

This study, concluded the researchers, suggests that there are significant benefits to switching from cigarettes to smokeless tobacco. Of course, they emphasized, the most ideal situation is where one quits all tobacco products and nicotine delivery systems, and this should remain the ultimate goal.

 

The content excerpted or reproduced in this article comes from a third-party, and the copyright belongs to the original media and author. If any infringement is found, please contact us to delete it. Any entity or individual wishing to forward the information, please contact the author and refrain from forwarding directly from here.

Namibia Moves to Tighten Laws on E-Cigarettes and Emerging Nicotine Products
Namibia Moves to Tighten Laws on E-Cigarettes and Emerging Nicotine Products
Namibia is moving to tighten regulation of e-cigarettes and other emerging nicotine products as part of broader tobacco control efforts. Deputy health minister Susan Ndjaleka said the government is reviewing the Tobacco Products Control Act to close regulatory gaps and address emerging tobacco products. Namibia is also working toward joining the Protocol to Eliminate Illicit Trade in Tobacco Products in order to curb the black market and protect public revenue.
Apr.17 by 2FIRSTS.ai
FDA Says It Will Not Take Enforcement Action Against Zone Nicotine Pouches Until Lawsuit Is Resolved
FDA Says It Will Not Take Enforcement Action Against Zone Nicotine Pouches Until Lawsuit Is Resolved
The U.S. Food and Drug Administration has told vape manufacturer Fontem US that it does not presently intend to take enforcement action against the company’s Zone nicotine pouches while litigation over the agency’s handling of the application remains unresolved.
Apr.07 by 2FIRSTS.ai
FDA and IKE Tech Hold Formal Listening Session on Youth Access and Illicit ENDS Products
FDA and IKE Tech Hold Formal Listening Session on Youth Access and Illicit ENDS Products
U.S. Food and Drug Administration’s Center for Tobacco Products held a formal listening session with IKE Tech LLC to discuss youth prevention at the point of use for ENDS products, the circulation of illicit products in the supply chain, and the regulatory treatment of software in tobacco products.
Apr.10 by 2FIRSTS.ai
Spanish parties PP and PSOE reach agreement on sales restrictions for e-cigarettes and nicotine pouches
Spanish parties PP and PSOE reach agreement on sales restrictions for e-cigarettes and nicotine pouches
Spain’s Popular Party and Socialist Party reached an agreement in the Joint Congress-Senate Commission for the Study of Addiction Problems and approved a non-binding motion calling for the sale of e-cigarettes, nicotine pouches and related products to be limited to authorized and controlled channels, such as tobacco shops and specialized stores, while excluding internet sales and general retail outlets.
Apr.27 by 2FIRSTS.ai
Product | Dual-Chamber 20ml E-liquid and 35,000 Puffs: JNR ShishaSip 35K Goes on Sale Online in the Spanish and French Markets
Product | Dual-Chamber 20ml E-liquid and 35,000 Puffs: JNR ShishaSip 35K Goes on Sale Online in the Spanish and French Markets
E-cigarette brand JNR has recently launched its new pod-based device, the JNR ShishaSip 35K, on its official website. The product adopts a dual-chamber structure with two built-in 10ml prefilled pods, bringing total e-liquid capacity to 20ml. It is officially claimed to provide about 35,000 puffs and features a 1050mAh battery, a 0.6Ω mesh coil, a display screen, and adjustable airflow. The product is already on sale through online channels in France and Spain at a price of EUR 15.90.
Apr.10 by 2FIRSTS.ai
FDA Filing Shows RIF Notices for 229 CTP Employees Were Largely Rescinded
FDA Filing Shows RIF Notices for 229 CTP Employees Were Largely Rescinded
A court declaration signed by FDA official Melanie M. Keller on March 24, 2026 detailed the status of previously issued reduction-in-force notices affecting employees at the Center for Tobacco Products (CTP).
Apr.01 by 2FIRSTS.ai